Elan subsidiary recieves seven US patents

The United States Patent and Trademark Office has issued Neuralab Limited, a subsidiary of Elan, seven patents for the companies' joint research on immunotherapeutic approaches to the prevention and treatment of Alzheimer's disease.

Six of the patents, all entitled "Prevention and treatment of amyloidogenic disease", are directed to the companies' active immunization approaches for treatment of Alzheimer's disease: US Patent Numbers 6,787,140 and 6,787,523 claim methods of prophylactically or therapeutically treating a disease characterized by a beta amyloid deposit in a patient by administering a beta amyloid peptide.